OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 11:42:24 2024-06-11 am EDT | ||
| 10.83 EUR | -2.78% |
|
| Current month | +31.52% | ||
| 1 month | +97.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 10.83 | -2.78% |
| 24-06-10 | 11.14 | -0.18% |
| 24-06-07 | 11.16 | +0.54% |
| 24-06-06 | 11.1 | +1.19% |
| 24-06-05 | 10.97 | +7.02% |
Real-time BOERSE MUENCHEN
Last update June 11, 2024 at 11:42 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1D7B |
| ISIN | DE000HD1D7B2 |
| Date issued | 2023-12-22 |
| Strike | 365.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.17 € |
|---|---|
| Lowest since issue | 2.71 € |
| Spread | 0.03 € |
| Spread % | 0.28% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483.3
USD
Average target price
463.5
USD
Spread / Average Target
-4.09%
- Stock Market
- Certificates
- Certificat
